Search results for "Protein"

showing 10 items of 21431 documents

In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy

2004

LDL can be subfractionated into buoyant (1.020-1.029 g/ml(-1)), intermediate (1.030-1.040 g/ml(-1)), and dense (1.041-1.066 g/ml(-1)) LDLs. We studied the rebound of these LDL-subfractions after LDL apheresis in seven patients with heterozygous familial hypercholesterolemia (FH) regularly treated by apheresis (58 +/- 9 years, LDL-cholesterol = 342 +/- 87 mg/dl(-1), triglycerides = 109 +/- 39 mg/dl(-1)) and high-dose statins. Apolipoprotein B (apoB) concentrations were measured in LDL subfractions immediately after and on days 1, 2, 3, 5, and 7 after apheresis. Compartmental models were developed to test three hypotheses: 1) that dense LDLs are derived from the delipidation of buoyant and in…

medicine.medical_specialtyVery low-density lipoproteinApolipoprotein Blow density lipoprotein metabolismFamilial hypercholesterolemiaQD415-436Biochemistrychemistry.chemical_compoundEndocrinologyInternal medicinerebound kineticsmedicinesmall dense low density lipoproteinsdensity gradient ultracentrifugationbiologyfamilial hypercholesterolemiaChemistryCholesterollow density lipoprotein subtypesCell BiologyMetabolismmedicine.diseaseEndocrinologyApheresisLDL apheresisbiology.proteinDensity gradient ultracentrifugationlipids (amino acids peptides and proteins)Journal of Lipid Research
researchProduct

Estimation of serum lipids in patients with Oral Submucous Fibrosis in India

2014

Objectives: Oral submucous fibrosis (OSMF) is the most prevalent precancerous condition in India. Low levels of lipids serves as a marker and prognostic indicator in the early detection of oral precancerous and cancerous states. In spite of the high prevalence and its potential to undergo malignant transformation, this condition has not widely been investigated with respect to the serum lipid levels. In the present study, an attempt was made to analyze the complete serum lipid profile, total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) choleste - rol, low density lipoprotein (LDL) cholesterol and very low density lipoprotein (VLDL) cholesterol in OSMF and controls. M…

medicine.medical_specialtyVery low-density lipoproteinBlood lipidsOdontologíaGastroenterologychemistry.chemical_compoundHigh-density lipoproteinInternal medicinemedicineGeneral DentistryOral Medicine and Pathologymedicine.diagnostic_testCholesterolbusiness.industryResearchmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludPrecancerous conditionEndocrinologychemistryOral submucous fibrosisLow-density lipoproteinUNESCO::CIENCIAS MÉDICASlipids (amino acids peptides and proteins)businessLipid profile
researchProduct

La auténtica dimensión del colesterol-no-HDL: colesterol aterogénico

2016

Lowe density lipoproteins (LDL) are the causal agent of cardiovascular diseases. In practice, we identify LDL with cholesterol transported in LDL (cLDL). So, cLDL has become the major target for cardiovascular prevention. Howewer, we have progressive evidences about the role of triglycerides rich lipoproteins, particularly those very low density lipoprotein (VLDL) in promotion and progression of atherosclerosis, that leads cholesterol in VLDL and its remanents as a potential therapeutic target. This feature is particularly important and of a great magnitude, in patients with hypertiglyceridemia. We can to considere, that the non-HDL cholesterol -cLDL+cVLDL+c-remmants+Lp(a)- is the real meas…

medicine.medical_specialtyVery low-density lipoproteinHigh risk patientsbusiness.industryCholesterolHypertriglyceridemia030204 cardiovascular system & hematologymedicine.disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePostprandialEndocrinologyCardiovascular preventionchemistryInternal medicineNon hdl cholesterolmedicinelipids (amino acids peptides and proteins)Pharmacology (medical)In patient030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessClínica e Investigación en Arteriosclerosis
researchProduct

Statins and diabetes.

2005

Lipid abnormalities play an important part in raising the cardiovascular risk in diabetic subjects. The main components of diabetic dyslipidemia are increased plasma triglycerides, low concentration of high-density lipoprotein cholesterol, preponderance of small, dense low-density lipoprotein, and excessive postprandial lipemia. Small, dense low-density lipoprotein, the elevation in remnant triglyceride-rich lipoprotein particles, and the low high-density lipoprotein are the most powerful atherogenic components. The coexistence of these three factors strongly aggravates the lipid accumulation in the arterial wall and the formation of atherosclerotic plaques. The position of diabetes in card…

medicine.medical_specialtyVery low-density lipoproteinHyperlipidemiasType 2 diabeteschemistry.chemical_compoundInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansTriglyceridebusiness.industrymedicine.diseaseLipidsEndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Therapeutic Lifestyle ChangesMetabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessLipoproteinSeminars in vascular medicine
researchProduct

Dietary cholate increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanisms

2001

To induce atherogenesis in mice, a high fat (HF) diet is supplemented with cholic acid (CA), which increases apoB-containing particles and lower apoA-I-containing particles. HF diet without CA increases levels of both HDL and LDL, suggesting that CA may be responsible for the elevation of LDL and lowering of HDL. The mechanism of dietary CA-induced lowering of apoA-I-containing particles has recently been reported. In this study, we examined the mechanism of CA- and HF-induced elevation of apoB-containing lipoproteins in mice. Mice were fed the following four diets: control chow (C), high fat high cholesterol, (HF), control and 0.5% cholate (CA), and HF + CA. Dietary CA increased the plasma…

medicine.medical_specialtyVery low-density lipoproteinSettore MED/09 - Medicina InternaMouseApolipoprotein Bmedicine.medical_treatmentDown-RegulationCholic AcidLipoproteins VLDLBiochemistryDietary cholateMicechemistry.chemical_compoundApolipoproteins ERibonucleasesDownregulation and upregulationInternal medicinemedicineAnimalsVitamin ERNA MessengerRNA Processing Post-TranscriptionalReceptorApolipoproteins BbiologyChemistryVitamin ECholic acidnutritional and metabolic diseasesCell BiologyBlotting NorthernDietLipoproteins LDLMice Inbred C57BLCholesterolEndocrinologyLiverReceptors LDLLDL receptorbiology.proteinlipids (amino acids peptides and proteins)Gene expressionHepatic lipaseApolipoprotein BCholatesDietary fatThe International Journal of Biochemistry & Cell Biology
researchProduct

Statins and metabolic syndrome

2003

Abstract Metabolic syndrome (MS) is a multifactorial condition that represents a risk factor for the development of diabetes mellitus (DMII) and cardiovascular disease (CVD). Statins may play a role on some modifiable clinical features of MS; in fact, whereas therapeutic lifestyle changes are mandatory for MS with a 10-year coronary heart disease (CHD) risk 20% and to correct the other associated lipid and non-lipid abnormalities. In fact, they have a VLDL lowering action in hypertriglyceridemia, they reduce the amount of small and dense LDL, they increase the HDL-C, they reduce the atherogenic lipoproteins, and they decrease the inflammatory marker levels.

medicine.medical_specialtyVery low-density lipoproteinbusiness.industryHypertriglyceridemianutritional and metabolic diseasesGeneral MedicineDiseasemedicine.diseaseEndocrinologyDiabetes mellitusInternal medicinemedicineCardiologylipids (amino acids peptides and proteins)RosuvastatinTherapeutic Lifestyle ChangesMetabolic syndromeRisk factorbusinessmedicine.drugInternational Congress Series
researchProduct

Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration

2013

Pasi Vottonen,1 Kai Kaarniranta,1,2 Ari Pääkkönen,3 Ina M Tarkka41Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland; 2Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; 3Department of Clinical Neurophysiology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; 4Department of Health Sciences, University of Jyväskylä, Jyväskylä, FinlandPurpose: Antivascular endothelial growth factor (VEGF) agents have been shown to improve visual acuity and prevent vision loss in exudative age-related macular degeneration. As the vision im…

medicine.medical_specialtyVisual acuityexudative age-related macular degenerationvisual acuitygenetic structuresvisual evoked potentialsVEGF receptorsta3112Cortical processingVisual processingText miningOphthalmologymedicinescalp-recorded EEGage-related eye diseasesOriginal Researchbiologybusiness.industryta3141Clinical OphthalmologyMacular degenerationmedicine.diseaseeye diseasesOphthalmologybiology.proteinElectrophysiological markerssense organsAnti vegf treatmentmedicine.symptombusinessClinical Ophthalmology
researchProduct

Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants

2010

An increasing number of patients receive anticoagulant therapy to prevent and treat arterial or venous thromboembolism. The major complication of anticoagulant therapy is the increase of the individual bleeding risk. All anticoagulant drugs can cause haemorrhages, that can sometimes be life-threatening. Although heparins and the vitamin K antagonists have been the most widely used anticoagulants for decades, the correct management of bleeding complications associated with these agents has been poorly studied. More recently, new anticoagulant drugs, both parenteral and oral, have been approved for clinical use. Currently, none of these new agents has a specific antidote, and little advise ca…

medicine.medical_specialtyVitamin Kmedicine.drug_classMorpholinesHemorrhageFactor VIIaThiophenesVitamin kFondaparinuxDabigatranRivaroxabanPolysaccharidesRisk FactorsDrug DiscoverymedicineHumansProtaminesIntensive care medicinePharmacologyRivaroxabanHeparinbusiness.industryAntithrombinAnticoagulantAnticoagulantsHeparinRecombinant ProteinsDabigatranFondaparinuxbeta-AlanineBenzimidazolesComplicationbusinessBleeding anticoagulantsmedicine.drugCurrent Pharmaceutical Design
researchProduct

Postprandial triglyceridaemia is modulated by insulin resistance but not by grade of obesity in abdominal and morbid obese subjects

2020

Background Obesity is associated with high cardiovascular risk. Postprandial lipidaemia has been associated with cardiovascular disease risk. Our aim was to identify whether anthropometric parameters, insulin resistance (IR) and/or fasting plasma triglycerides may determine postprandial changes in lipoprotein concentrations in abdominal and morbid obese subjects. Methods We have studied 20 non-diabetic, normolipidaemic subjects with abdominal obesity, 20 morbid obese subjects and 20 healthy individuals, that have similar age and gender. In all of them a standardised oral fat load test (OFLT) with unsaturated fat was performed. Results During the OFLT, the postprandial triglycerides response…

medicine.medical_specialtyWaist030204 cardiovascular system & hematologyGastroenterologyBody Mass Index03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceInternal medicinemedicineHumansInsulin030212 general & internal medicineTriglyceridesAbdominal obesitybusiness.industryUnsaturated fatGeneral MedicinePostprandial Periodmedicine.diseaseObesityObesity MorbidPostprandialchemistryObese subjectsInsulin Resistancemedicine.symptombusinessLipoproteinInternational Journal of Clinical Practice
researchProduct

Both poor cardiorespiratory and weak muscle fitness are related to a high concentration of oxidized low-density lipoprotein lipids

2011

Good physical fitness is associated with favorable serum lipids. Oxidized low-density lipoprotein (ox-LDL) could be even more atherogenic than serum lipids. We studied the association of ox-LDL and serum lipids with physical fitness. Healthy young (mean age 25 years) men (n=846) underwent maximal oxygen uptake (VO(2max)) and muscle fitness index (MFI) tests and completed a leisure-time physical activity (LTPA) questionnaire. Age (ANCOVA1), age+waist circumference+systolic blood pressure+fasting blood glucose+smoking (ANCOVA3) were used as covariates. The groups with the lowest VO(2max), MFI and LTPA had 23%, 16% and 8% higher concentrations of ox-LDL than the groups with the highest VO(2max…

medicine.medical_specialtyWaistbusiness.industryPhysical fitnessOxidized low density lipoproteinBlood lipidsVO2 maxPhysical Therapy Sports Therapy and RehabilitationCardiorespiratory fitnessEndocrinologyBlood pressureInternal medicinemedicinelipids (amino acids peptides and proteins)Orthopedics and Sports MedicinebusinessLipoproteinScandinavian Journal of Medicine & Science in Sports
researchProduct